ガバペンチンの世界市場

ガバペンチンの世界市場は2030年までに28億米ドルに達する見込み

2024年に22億米ドルと推定されるガバペンチンの世界市場は、2024年から2030年にかけてCAGR 4.0%で成長し、2030年には28億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである錠剤投薬は、CAGR 3.8%を記録し、分析期間終了時には15億米ドルに達すると予測されます。カプセル剤セグメントの成長率は、分析期間中CAGR 4.5%と推定されます。

米国市場は5億9,470万米ドルと推定、中国はCAGR 7.4％で成長予測

米国のガバペンチン市場は、2024年に5億9,470万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに5億6,190万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と3.1%と予測されています。欧州では、ドイツがCAGR 2.4%で成長すると予測されています。

世界のガバペンチン市場- 主要動向と促進要因のまとめ

ガバペンチンが疼痛管理や神経疾患で広く使われるようになった理由とは？

ガバペンチンは、神経シグナル伝達を調節し、神経に関連する不快感を軽減する効果があるため、神経障害性疼痛、てんかん、レストレスレッグス症候群（RLS）の管理において最も広く処方される医薬品のひとつとなっています。もともと抗けいれん薬として開発されたガバペンチンは、慢性的な神経痛を緩和する作用があることから、てんかん治療以外にも使用されるようになり、帯状疱疹後神経痛、糖尿病性神経障害、線維筋痛症に悩む患者にとって好ましい選択肢となっています。慢性疼痛疾患や神経疾患の世界の増加により、ガバペンチンの需要はプライマリ・ケアと専門医療の両方で急増しています。

ガバペンチンの人気に貢献している重要な要因の一つは、オピオイドベースの鎮痛薬と比較して比較的良好な安全性プロファイルです。オピオイド危機が進行し、オピオイド処方に対する規制が厳しくなる中、慢性疼痛管理のための非オピオイド代替薬として、ガバペンチンに注目する医師が増えています。さらに、ガバペンチンは、特に術後の回復や緩和ケアなど、多剤併用による疼痛管理戦略の一環として頻繁に使用されており、その治療用途はさらに拡大しています。疼痛管理が進化する中、ガバペンチンは、多様な患者集団における神経障害性疼痛や慢性疼痛への対応において、中心的な役割を果たし続けています。

製薬技術革新は、ガバペンチンの製剤と投与方法をどのように向上させていますか？

医薬製剤の進歩により、ガバペンチンの有効性と生物学的利用能が大幅に改善され、疼痛緩和と発作抑制に効果的です。徐放性（ER）製剤や胃内滞留性製剤は、治療効果を持続させ、投与回数を減らし、患者のアドヒアランスを向上させるために開発されました。さらに、経皮パッチやナノ粒子をベースとした製剤などの新しいドラッグデリバリーシステムの調査により、ガバペンチンの薬物動態が改善され、高用量の経口投与に伴う副作用が最小限に抑えられています。

また、ガバペンチンと抗うつ薬や筋弛緩薬などの他の薬剤との併用も、特に複雑な疼痛症候群や気分障害の治療において、臨床現場で支持を集めています。さらに、AIを活用した創薬や製剤研究は、製薬会社が効能や作用機序を改善したガバペンチン誘導体を最適化するのに役立っています。プレシジョン・メディシンの進歩に伴い、個々の患者の遺伝や代謝プロファイルに合わせた個別化ガバペンチン療法の可能性が、神経学や疼痛管理における新たな関心分野となってきています。

ガバペンチンの需要を牽引している治療領域とヘルスケア分野は？

神経学と疼痛管理は、ガバペンチンの需要を牽引する主要な医療専門分野であり、てんかん、神経障害性疼痛、慢性疼痛障害の治療に広く使用されています。疼痛クリニック、リハビリテーションセンター、老人介護施設は、ガバペンチンの処方で最も急成長している分野のひとつです。加齢に伴う神経損傷や退行性神経疾患の管理に頻繁に使用されるからです。さらに、遠隔医療やデジタルヘルスプラットフォームの拡大により、慢性疼痛に悩む患者にとってガバペンチンがより利用しやすくなり、遠隔での処方管理やモニタリングが可能になりました。

獣医療分野もガバペンチンの成長市場として浮上しており、コンパニオンアニマル、特に犬猫の疼痛や不安の管理に使用されるケースが増えています。動物医療における術後疼痛管理プロトコルの増加は、動物用に調整されたガバペンチン製剤の需要増加にさらに寄与しています。さらに、不安障害や双極性障害などの気分障害の治療への応用が期待される薬剤の調査も進んでおり、精神科医療での治療に新たな道が開けています。

市場成長を牽引する主な要因とは？

ガバペンチン市場の成長は、神経障害性疼痛の有病率の上昇、非オピオイド性疼痛の代替薬としての採用の増加、薬剤製剤技術の進歩など、いくつかの要因によって牽引されています。疼痛管理プログラムや緩和ケアイニシアチブの継続的な拡大が、特に高齢化社会におけるガバペンチンの需要を促進しています。さらに、ガバペンチンの動物用医薬品や新たな精神医学への応用が拡大していることも、市場の可能性をさらに広げています。製薬会社が徐放性製剤や個別化治療アプローチで技術革新を続ける中、ガバペンチンは今後も世界中で神経障害性疼痛や発作管理の要であり続けると予想されます。

セグメント

剤形（錠剤、カプセル剤、内服液剤）、タイプ（ジェネリックタイプ、ブランドタイプ）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）、用途（てんかん用途、神経障害性疼痛用途、むずむず脚症候群用途、その他用途）

調査対象企業の例

• Actavis Elizabeth LLC
• Alkem Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• Apotex Inc.
• Ascend Laboratories, LLC
• Assertio Holdings, Inc.
• Aurobindo Pharma Limited
• Cipla Limited
• Glenmark Pharmaceuticals Ltd.
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Pfizer Inc.
• Sandoz（a Novartis Division）
• Sciegen Pharmaceuticals Inc.
• Strides Pharma Science Limited
• Sun Pharmaceutical Industries Ltd.
• Taro Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Viatris Inc.

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Gabapentin Market to Reach US$2.8 Billion by 2030

The global market for Gabapentin estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.8 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Tablet Dosage, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Capsule Dosage segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$594.7 Million While China is Forecast to Grow at 7.4% CAGR

The Gabapentin market in the U.S. is estimated at US$594.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$561.9 Million by the year 2030 trailing a CAGR of 7.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Gabapentin Market - Key Trends & Drivers Summarized

Why is Gabapentin Gaining Widespread Use in Pain Management and Neurological Disorders?

Gabapentin has become one of the most widely prescribed medications for managing neuropathic pain, epilepsy, and restless leg syndrome (RLS), owing to its effectiveness in modulating nerve signaling and reducing nerve-related discomfort. Originally developed as an anticonvulsant, gabapentin’s ability to alleviate chronic nerve pain has expanded its use beyond epilepsy treatment, making it a preferred option for patients suffering from postherpetic neuralgia, diabetic neuropathy, and fibromyalgia. With a growing global burden of chronic pain disorders and neurological conditions, the demand for gabapentin has surged in both primary care and specialty medical practices.

One of the key factors contributing to gabapentin’s popularity is its relatively favorable safety profile compared to opioid-based pain medications. Amid the ongoing opioid crisis and increasing regulatory scrutiny on opioid prescriptions, physicians are increasingly turning to gabapentin as a non-opioid alternative for managing chronic pain. Additionally, gabapentin is frequently used as part of multimodal pain management strategies, particularly in post-surgical recovery and palliative care, further expanding its therapeutic applications. As pain management practices evolve, gabapentin continues to play a central role in addressing neuropathic and chronic pain conditions across diverse patient populations.

How is Pharmaceutical Innovation Enhancing Gabapentin Formulations and Delivery Methods?

Advancements in pharmaceutical formulations have significantly improved the efficacy and bioavailability of gabapentin, making it more effective in pain relief and seizure control. Extended-release (ER) and gastro-retentive formulations have been developed to provide sustained therapeutic effects, reducing the frequency of dosing and improving patient adherence. Additionally, research into novel drug delivery systems, such as transdermal patches and nanoparticle-based formulations, is enhancing gabapentin’s pharmacokinetics and minimizing side effects associated with high oral doses.

The combination of gabapentin with other medications, such as antidepressants and muscle relaxants, is also gaining traction in clinical practice, particularly for treating complex pain syndromes and mood disorders. Furthermore, AI-driven drug discovery and formulation research are helping pharmaceutical companies optimize gabapentin derivatives with improved potency and targeted mechanisms of action. As precision medicine advances, the potential for personalized gabapentin therapy tailored to individual patient genetics and metabolic profiles is becoming an emerging area of interest in neurology and pain management.

Which Therapeutic Areas and Healthcare Sectors Are Driving Demand for Gabapentin?

Neurology and pain management are the leading medical specialties driving demand for gabapentin, with widespread use in treating epilepsy, neuropathic pain, and chronic pain disorders. Pain clinics, rehabilitation centers, and geriatric care facilities are among the fastest-growing segments for gabapentin prescriptions, as it is frequently used to manage age-related nerve damage and degenerative neurological conditions. Additionally, the expansion of telemedicine and digital health platforms has made gabapentin more accessible to patients suffering from chronic pain, allowing for remote prescription management and monitoring.

The veterinary medicine sector has also emerged as a growing market for gabapentin, with increasing use in managing pain and anxiety in companion animals, particularly cats and dogs. The rise in post-operative pain management protocols in veterinary care has further contributed to increased demand for gabapentin formulations tailored for animal use. Additionally, ongoing research into the drug’s potential applications in treating mood disorders, including anxiety and bipolar disorder, has opened new avenues for its therapeutic use in psychiatric medicine.

What Key Factors Are Driving Market Growth?

The growth in the gabapentin market is driven by several factors, including the rising prevalence of neuropathic pain conditions, increasing adoption as a non-opioid pain alternative, and advancements in drug formulation technology. The ongoing expansion of pain management programs and palliative care initiatives has fueled demand for gabapentin, particularly among aging populations. Additionally, the growing use of gabapentin in veterinary medicine and emerging psychiatric applications has further expanded its market potential. As pharmaceutical companies continue to innovate with extended-release formulations and personalized treatment approaches, gabapentin is expected to remain a cornerstone of neuropathic pain and seizure management worldwide.

SCOPE OF STUDY:

The report analyzes the Gabapentin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Dosage Form (Tablet Dosage, Capsule Dosage, Oral Solution Dosage); Type (Generic Type, Branded Type); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel); Application (Epilepsy Application, Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Actavis Elizabeth LLC
• Alkem Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• Apotex Inc.
• Ascend Laboratories, LLC
• Assertio Holdings, Inc.
• Aurobindo Pharma Limited
• Cipla Limited
• Glenmark Pharmaceuticals Ltd.
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Pfizer Inc.
• Sandoz (a Novartis Division)
• Sciegen Pharmaceuticals Inc.
• Strides Pharma Science Limited
• Sun Pharmaceutical Industries Ltd.
• Taro Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Torrent Pharmaceuticals Ltd.
• Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Gabapentin - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Neuropathic Pain and Epilepsy Drives Demand for Gabapentin-Based Therapies
  • Increased Off-Label Prescribing for Anxiety, Migraine, and Fibromyalgia Expands Market Scope
  • Expansion of Generic Manufacturing Boosts Accessibility and Lowers Treatment Cost Globally
  • Surge in Geriatric Population With Chronic Pain Disorders Supports Long-Term Gabapentin Use
  • Regulatory Oversight and Abuse Potential Monitoring Drives Safe Use Frameworks for Gabapentin
  • Growth of Post-Herpetic Neuralgia and Diabetic Neuropathy Cases Fuels Prescription Volume
  • Increased Inclusion of Gabapentin in National Formularies Enhances Public Health Sector Utilization
  • Product Innovation in Extended-Release and Abuse-Deterrent Formulations Strengthens Compliance
  • Integration Into Multimodal Pain Management Regimens Supports Reduced Opioid Dependence
  • Rising Use in Veterinary Medicine for Canine and Feline Neurological Conditions Expands Niche Applications
  • Support From Clinical Guidelines Reinforces Gabapentin as First-Line for Multiple Neuropathic Disorders
  • Expansion of Hospital Formularies and Hospice Care Protocols Promotes Institutional Demand
  • Evolving Market Dynamics in Pain Therapeutics Encourage Co-Prescription With Muscle Relaxants
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gabapentin Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gabapentin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gabapentin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Gabapentin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Tablet Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Tablet Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Tablet Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Capsule Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Capsule Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Capsule Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Oral Solution Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Oral Solution Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Oral Solution Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Neuropathic Pain Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Neuropathic Pain Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Neuropathic Pain Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Restless Legs Syndrome Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Restless Legs Syndrome Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Restless Legs Syndrome Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Epilepsy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Epilepsy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Epilepsy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Generic Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Generic Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Generic Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Branded Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Branded Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Branded Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• JAPAN
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• CHINA
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• EUROPE
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Gabapentin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Gabapentin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Gabapentin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• FRANCE
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• GERMANY
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 140: UK Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Gabapentin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Gabapentin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Gabapentin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• INDIA
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 215: India Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Gabapentin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Gabapentin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Gabapentin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Gabapentin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Gabapentin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Gabapentin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
• AFRICA
  • Gabapentin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Gabapentin by Dosage Form - Tablet Dosage, Capsule Dosage and Oral Solution Dosage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Gabapentin by Dosage Form - Percentage Breakdown of Value Sales for Tablet Dosage, Capsule Dosage and Oral Solution Dosage for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Gabapentin by Application - Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Gabapentin by Application - Percentage Breakdown of Value Sales for Neuropathic Pain Application, Restless Legs Syndrome Application, Other Applications and Epilepsy Application for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Gabapentin by Type - Generic Type and Branded Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Gabapentin by Type - Generic Type and Branded Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Gabapentin by Type - Percentage Breakdown of Value Sales for Generic Type and Branded Type for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Gabapentin by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Gabapentin by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Online Pharmacies Distribution Channel for the Years 2015, 2025 & 2030

IV. COMPETITION